NxStage Medical, Inc. (NASDAQ:NXTM) SVP Winifred L. Swan sold 3,500 shares of the company’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $25.35, for a total transaction of $88,725.00. Following the completion of the sale, the senior vice president now directly owns 14,270 shares of the company’s stock, valued at $361,744.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
NxStage Medical, Inc. (NASDAQ NXTM) opened at $24.77 on Friday. NxStage Medical, Inc. has a 1 year low of $20.45 and a 1 year high of $30.80. The firm has a market cap of $1,640.57, a PE ratio of -353.86 and a beta of -0.08.
A number of brokerages have recently commented on NXTM. Canaccord Genuity reaffirmed a “hold” rating and issued a $30.00 target price on shares of NxStage Medical in a report on Tuesday, October 17th. Zacks Investment Research upgraded shares of NxStage Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, Northland Securities reiterated a “hold” rating and set a $30.00 price target on shares of NxStage Medical in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating and nine have issued a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $30.25.
A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC grew its position in NxStage Medical by 31.8% during the second quarter. FMR LLC now owns 9,860,278 shares of the medical device company’s stock worth $247,197,000 after buying an additional 2,378,077 shares during the period. Alpine Associates Management Inc. acquired a new position in NxStage Medical during the third quarter worth about $110,163,000. Magnetar Financial LLC acquired a new position in NxStage Medical during the third quarter worth about $84,927,000. Eagle Asset Management Inc. grew its position in NxStage Medical by 26.6% during the second quarter. Eagle Asset Management Inc. now owns 2,573,603 shares of the medical device company’s stock worth $64,520,000 after buying an additional 540,103 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of NxStage Medical by 239,738.6% in the third quarter. JPMorgan Chase & Co. now owns 1,870,741 shares of the medical device company’s stock valued at $51,502,000 after purchasing an additional 1,869,961 shares during the last quarter. Institutional investors own 85.35% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/14/nxstage-medical-inc-nxtm-svp-winifred-l-swan-sells-3500-shares.html.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.